USA - NASDAQ:ILMN - US4523271090 - Common Stock
The current stock price of ILMN is 95.03 USD. In the past month the price decreased by -7.07%. In the past year, price decreased by -36.55%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.92 | 210.82B | ||
| DHR | DANAHER CORP | 27.76 | 153.24B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 143.51 | 46.81B | ||
| A | AGILENT TECHNOLOGIES INC | 26.28 | 40.60B | ||
| IQV | IQVIA HOLDINGS INC | 18.73 | 37.03B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.09 | 28.72B | ||
| WAT | WATERS CORP | 28.08 | 20.44B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 40.29 | 20.48B | ||
| MEDP | MEDPACE HOLDINGS INC | 40.88 | 16.42B | ||
| TEM | TEMPUS AI INC | N/A | 15.43B | ||
| ICLR | ICON PLC | 12.58 | 12.91B | ||
| RVTY | REVVITY INC | 19.9 | 11.06B |
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
ILLUMINA INC
5200 Illumina Way
San Diego CALIFORNIA 92122 US
CEO: Francis A. deSouza
Employees: 9000
Phone: 18582024500
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
The current stock price of ILMN is 95.03 USD. The price decreased by -2.83% in the last trading session.
ILMN does not pay a dividend.
ILMN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
ILMN stock is listed on the Nasdaq exchange.
You can find the ownership structure of ILLUMINA INC (ILMN) on the Ownership tab.
ChartMill assigns a technical rating of 1 / 10 to ILMN. When comparing the yearly performance of all stocks, ILMN is a bad performer in the overall market: 87.52% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to ILMN. ILMN scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months ILMN reported a non-GAAP Earnings per Share(EPS) of 4.16. The EPS increased by 352.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.37% | ||
| ROA | 20.67% | ||
| ROE | 55.71% | ||
| Debt/Equity | 0.66 |
29 analysts have analysed ILMN and the average price target is 113.85 USD. This implies a price increase of 19.8% is expected in the next year compared to the current price of 95.03.
For the next year, analysts expect an EPS growth of 87.51% and a revenue growth -1.43% for ILMN